Jill Lacy MD

Associate Professor of Medicine (Medical Oncology)

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program

Medical Oncology

Education & Training

  • M.D., Yale University (1978)
  • Resident, Yale University School of Medicine , Internal Medicine (1979 - 1982)
  • Fellow, Yale University School of Medicine , Oncology (1982 - 1985)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients


Clinical Interests

Colorectal cancer; pancreatic cancer; esophageal cancer; gastric cancer; gall bladder cancer; anal cancer; biliary cancer; liver cancer; neuroendocrine tumors; brain tumors; non-Hodgkin's lymphoma (NHL); Hodgkin's disease; Kaposi's sarcoma


Cancers Treated

Anal, Brain, Colon (including Rectum), Esophagus, Gall Bladder, Gastrointestinal (including Stomach), Kaposi's Sarcoma, Pancreas, Unknown primary


Board Certifications

  • Internal Medicine, Board Certified (1982)
  • Medical Oncology, Board Certified (1991)

Clinical Trials

ConditionsStudy Title
Colorectal Cancer and ColonC80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Stage IB Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, and EsophagusRTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma {CIRB}
PancreasPhase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Bladder, Breast - Female, Colon, Lung, Melanoma, skin, Other Endocrine System, Other Respiratory and Intrathoracic Organs, Other Urinary, Ovary, Rectum, and StomachA Phase I, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Bladder, Breast - Female, Lung, Pancreas, and StomachA Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

More Clinical Trials...

Edit Profile